Vitros 950 Chemistry System

HOME >> MEDICINE >> PRODUCTS

Products

Vitros 950 Chemistry System

Company

Ortho-Clinical Diagnostics

Item

Vitros 950 Chemistry System

Features

No preparation of reagents for use
Minimal interference from hemolysis
Lipemia & bilirubin
Small sample size requirements
Up to 900 results per hour
On-board capacity for all assays
Primary tube sampling
Open architecture design for use with laboratory automation systems
Easy to use touchscreen operator interface
Flexible processing for manual, stat or automated testing

Description

The Vitros 950 provides power and efficiency to meet the needs of high volume testing facilities. With fast throughput of up to 900 results per hour, the Vitros 950 can store and perform the full complement of Vitros chemistry assays on a continuous basis.

Info

Ortho-Clinical DiagnosticsCall Ortho-Clinical Diagnostics to buy products (US and Canada only; other locations use number below) USA

1-866-802-9580

Customer Service: 1-800-828-6316
Web site: http://www.orthoclinical.com

TAG: Vitros Chemistry System

The cemented hip joint prosthesis system.

The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem.

Medicine Products:

The MY stem The Natural-Hip Family - Low Demand (LD)The Natural-Hip Family - Specialty Porous Collared HA The Natural-Hip Family - High Demand Porous (collared)

(Date:8/20/2008)...r-old Contestant Wins Trip to Little League Baseba... The National Spit Tobacco Education,Program (NSTE...st today,and encouraged young baseball players to...ddiction and the health risks of using tobacco pro...year,s slogan contest winner is,Joe Reck, a nine-y...

(Date:8/20/2008)...cently enacted Medicare Improvement Law immediatel...re Advantage insurance companies .../PRNewswire/ -- When the House and Senate,overrode...gislation,protecting Medicare beneficiaries, they ...e Advantage plans during one of the busiest months...

(Date:8/20/2008)...T CREEK, Calif., Aug. 20 /PRNewswire-FirstCall/ --... reported preliminary income from,continuing opera...f $27.5,million, or $0.76 per diluted share, inclu...er diluted share, related to provisions for store,... a 6.8 percent increase,compared with income from ...

(Date:8/20/2008)...FIELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/Cha...llness Promotion will give thousands of,Detroit me...ALTHY LIVING,FOR KIDS" program. This year the prog....m. to 5 p.m. at the Charles H. Wright Museum of A...77, "Healthy Living for Kids",has provided free im...

[0] Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use [0] Medicare Advantage Plans Struggle to Comply With New Federal Law [0] Longs Drug Stores Corporation Reports Second Quarter Results [0] WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History

...-moon has urged the G8 summit of the world's top i...limate change, warning that inaction would be cos...at Heiligendamm in Germany, Ban said the eight par...d implement a long-term global framework to tackle...

...cannot keep up with demand. Two experts in this we...people want to donate unless there is evidence to...0% of the UK population support organ donation, ye...h to donate, writes Veronica English, Deputy Head ...

...ogical treatments such as hypnotherapy have the po...el syndrome (IBS), say researchers in this weeks ...nal physical treatments often do not work very wel... that their symptoms are being ignored, downplayed...

...aiming an interesting manifestation of post trauma...n. And when he frequented chat rooms while at w...ant, IBM, fired him. Now the 58-year old James P... suing them for $ 5 million for "wrongful dismissa...

Other Medicine News:Health News:Is Presumed Consent the Answer to Organ Shortages? 2 Health News:Hypnotherapy may Help Patients With Irritable Bowel Syndrome 2 Health News:Sacked Employee Says Stress Led to His Sex Addiction 2

UN Secretary General Urges G8 Summit to Act on Climate Change Is Presumed Consent the Answer to Organ Shortages?Hypnotherapy may Help Patients With Irritable Bowel Syndrome Sacked Employee Says Stress Led to His Sex Addiction

(Date:8/14/2008)...BiTE) showing clinical benefit in cancer,patients;...gnize and attack canc...tCall/ -- Micromet, Inc.,(Nasdaq: MITI ), a bioph...,antibodies for the treatment of cancer, inflammat...cation of a Phase 1 clinical study(1) on its,BiTE(...

(Date:8/14/2008)...gin in late 2008 or in early 2009 -, SAN CARLOS, ...Inc.,(Nasdaq: NUVO ) today announced positive res...U172, demonstrating that the direct thrombin,inhib...on with a rapid,return toward baseline after the i...NU172 has the potential to address many of the lim...

(Date:8/13/2008)...es Insulin Sensitivity and Reduces,Inflammatory Ma..., PHOENIX, Aug. 13 /PRNewswire-USNewswire/ -- A s...esearch Institute (KLRI) found that a diet,high in...ces inflammatory,markers, but does not alter endoc...shed in Hormones and Metabolic Research., "As we ...

(Date:8/13/2008)...12 could provide therapeutic benefit in ... CARLSBAD, Calif., Aug. 13 /PRNewswire-FirstCall/ ...ounced today it has initiated a,Phase 1 study of I...oduction of C-reactive protein (CRP). CRP levels a...of diseases including cardiovascular disease,Croh...

Breaking Medicine Technology:Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 2 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 3 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 4 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 5 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 6 Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 2 Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 3 Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 4 Study Shows Benefits of a High Omega-3 Diet in Older Adults 2 Study Shows Benefits of a High Omega-3 Diet in Older Adults 3 Isis Initiates Clinical Trial of CRP Drug 2 Isis Initiates Clinical Trial of CRP Drug 3 Childrens HeartLink 28R 29 to Benefit From Sales of Kim 26 Scotts Gourmet Pretzels 28R 29 Valentines Day Love Knot Sampler 28TM 29 10034 1 Childrens HeartLink 28R 29 to Benefit From Sales of Kim 26 Scotts Gourmet Pretzels 28R 29 Valentines Day Love Knot Sampler 28TM 29 10034 2 ImpactRx Tracks Decline in Zetia and Vytorin Prescribing 1268 1 ImpactRx Tracks Decline in Zetia and Vytorin Prescribing 1268 2 ImpactRx Tracks Decline in Zetia and Vytorin Prescribing 1268 3 Deficient regulators in the immune system responsible for type 1 diabetes 10029 1 Deficient regulators in the immune system responsible for type 1 diabetes 10029 2 Accuro Healthcare Solutions Inc Files Registration Statement for Proposed Initial Public Offering 10026 1

[0] Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab [0] Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 [0] Study Shows Benefits of a High Omega-3 Diet in Older Adults [0] Isis Initiates Clinical Trial of CRP Drug

...--(BUSINESS WIRE)--Apr 11, 2007 - Cyclacel,Pharmac...unced,today that scientists from the company will ...pacitabine and seliciclib, the company,s,most adva...results,will be reported in two poster presentatio...can Association for Cancer Research,(AACR) taking ...

...INESS WIRE)--Apr 11, 2007 - New data,supporting th... of,the most advanced investigational oral proteas...s (HCV) infection, will be presented,at the 42nd A...Study of the Liver (EASL) in Barcelona this week. ...e been accepted for presentation,at the EASL confe...

Other Medicine Technology:Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR 2 Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR 3 Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR 4 Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 2 Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 3 Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 4 Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 5 Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 6

Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL)